MedTrace Logo

SafeTy and Efficacy of Preventative CoVID Vaccines

NCT05208983 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1286

Last updated 2023-01-05

No results posted yet for this study

Summary

The STOPCoV study is a decentralized study comparing COVID-19 vaccine specific antibody levels at 24 weeks after final vaccine dose. We plan to study the safety and immunogenicity of COVID-19 vaccine(s) in community dwelling persons 70 years and over relative to a younger group (aged 30 - 50 years).

Conditions

  • COVID-19 Virus Infection
  • Vaccine Response

Interventions

BIOLOGICAL

mRNA Vaccines or Viral vector-based vaccines for COVID

Participants receiving an approved COVID vaccine

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Samuel Lunenfeld Research Institute, Mount Sinai Hospital

    collaborator OTHER

  • Public Health Agency of Canada (PHAC)

    collaborator OTHER_GOV

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Sharon Walmsley, MD · University Health Network, Toronto

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-06
Primary Completion
2024-03-31
Completion
2024-04-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05208983 on ClinicalTrials.gov